{"id":87233,"date":"2024-02-01T11:12:00","date_gmt":"2024-02-01T14:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/introducing-citelines-trialscope-disclose-core-data\/"},"modified":"2024-02-01T11:12:00","modified_gmt":"2024-02-01T14:12:00","slug":"introducing-citelines-trialscope-disclose-core-data","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/introducing-citelines-trialscope-disclose-core-data\/","title":{"rendered":"Introducing Citelines TrialScope Disclose: Core Data"},"content":{"rendered":"

Citeline<\/b><\/p>\n

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) — Submitting clinical trial disclosures across different regions can be a fragmented, cumbersome process. Citelines new TrialScope Disclose: Core Data is a unified registry submission platform that helps consolidate and streamline clinical trial disclosure processes.<\/p>\n

TrialScope Disclose: Core Data features the required global data fields in a single form, allowing for one-time disclosure across multiple registries, including ClinicalTrials.gov, CTIS and jRCT, with more registries being added in the near future. Core Data eliminates duplicate data entry across registries, streamlining the review\/approval process for senior staff and ensuring consistency and efficiency, while its built-in validations and compliance checks reduce risks.<\/p>\n

Managing clinical trial disclosures across multiple registries is often done in a piecemeal fashion, leaving the process open to errors and inconsistencies that can lead to noncompliance, says David Laky, General Manager, Clinical & Regulatory, Citeline. TrialScope Disclose: Core Data allows for approval and submission from a single source of truth, helping to simplify, harmonize and accelerate the clinical trial disclosure process.<\/p>\n

TrialScope Disclose has been the leader in helping clinical trial sponsors prepare their studies for public disclosure for over a decade. With the addition of the Core Data platform, TrialScope Disclose continues to provide cutting-edge disclosure technology to enable seamless regulatory compliance.<\/p>\n

Learn more about Citelines TrialScope Disclose<\/a>.<\/p>\n

About Citeline<\/strong>
Citeline, a Norstella<\/a> company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.<\/p>\n

Citelines global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the worlds most trusted health science partners, visit\u00a0Citeline<\/u><\/a> and follow on LinkedIn<\/a> and X<\/a>.<\/p>\n

Citeline PR contact:<\/strong>
Diffusion PR for Citeline
citeline@diffusionpr.com<\/u><\/a>
(213) 318-4500<\/p>\n<\/p>\n



\n\"Primary<\/a><\/p>\n

A OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP<\/b> e sao de inteira responsabilidade da GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Citeline NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) — Submitting clinical trial disclosures across different regions can be a fragmented, cumbersome process. Citelines new TrialScope Disclose:","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-87233","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/87233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=87233"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/87233\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=87233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=87233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=87233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}